Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
February 1, 2016
- FDA OKs Eisai’s Halaven for Liposarcoma
February 1, 2016
- Chugai Positions Mid-Sized Molecule Drugs as Third Pillar of Business, Aims to Produce First Candidate within 3 Years
February 1, 2016
- Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan
January 29, 2016
- Kadcyla Development for Gastric Cancer Discontinued: Chugai
January 29, 2016
- Chugai Delivers Record Earnings, but Pegasys Falters on IFN-Free Hep C Therapies
January 29, 2016
- Shionogi, Nissan Chemical Ink Collaboration Pact on Antifungals
January 29, 2016
- Sumitomo Dainippon to Revise 5-Year Business Plan
January 29, 2016
- Ferring Empowers Japan Unit, Local Head Mark Noggle Doubles as CEO
January 29, 2016
- Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
January 29, 2016
- Shionogi Files Japan NDA for ADHD Drug Licensed from Shire
January 28, 2016
- Mochida Seeks Adenomyosis Indication for Dinagest
January 28, 2016
- 140 Hep C Patients Receive Viekirax in 1st Month
January 27, 2016
- Mochida Set to Achieve 10 Billion Yen Generic Sales in FY2015
January 27, 2016
- MSD Joins with Venture Capital to Offer BD Support for Health-Tech Startups
January 27, 2016
- Mundipharma to Merge Spectrum Unit in March, Become MAH for Zevalin
January 26, 2016
- Kyowa Kirin to Market Sandoz’s Rituximab Biosimilar in Japan
January 26, 2016
- Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs
January 21, 2016
- Maruho, Galderma Team Up to Develop, Market Skin Treatments in Japan
January 19, 2016
- Toa Eiyo to Take Over Astellas’s Marketing Authorization for Cibenol
January 19, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…